Display options
Cite
Bejarano PF, Herrero JF. A critical appraisal of COX-2 selective inhibition and analgesia: how good so far?. Pain Pract. 2003;3(3):201-17doi: 10.1046/j.1533-2500.2003.03024.x.
Bejarano, P. F., & Herrero, J. F. (2003). A critical appraisal of COX-2 selective inhibition and analgesia: how good so far?. Pain practice : the official journal of World Institute of Pain, 3(3), 201-17. https://doi.org/10.1046/j.1533-2500.2003.03024.x
Bejarano, Pedro F, and Herrero, Juan F. "A critical appraisal of COX-2 selective inhibition and analgesia: how good so far?." Pain practice : the official journal of World Institute of Pain vol. 3,3 (2003): 201-17. doi: https://doi.org/10.1046/j.1533-2500.2003.03024.x
Bejarano PF, Herrero JF. A critical appraisal of COX-2 selective inhibition and analgesia: how good so far?. Pain Pract. 2003 Sep;3(3):201-17. doi: 10.1046/j.1533-2500.2003.03024.x. PMID: 17147669.
Copy Download .nbib Format: NLM
Share it on

Pain Pract. 2003 Sep;3(3):201-17. doi: 10.1046/j.1533-2500.2003.03024.x.

A critical appraisal of COX-2 selective inhibition and analgesia: how good so far?.

Pain practice : the official journal of World Institute of Pain

Pedro F Bejarano, Juan F Herrero

Affiliations

  1. Department of Anesthesiology, Critical and Palliative Care, Centro Oncológico MD Anderson International-Espana, Madrid, Spain. [email protected]

PMID: 17147669 DOI: 10.1046/j.1533-2500.2003.03024.x

Abstract

The development of COX-2 selective inhibitors has opened a new era of clinical investigation in NSAIDs. Discussion of the established concepts of inflammation and therapeutical uses of these drugs has changed the rationale for its clinical use and therapeutic labeling of these drugs. A comprehensive discussion across basic science and clinical areas involved in each of these concepts is presented. This led to a remarkable re-evaluation of our insights on their traditionally proposed mechanisms of analgesia, their side-effects, and the clinical indication of NSAIDs as "over the counter" pain killers. This may shift physicians toward a more rational use of this drug class.

Publication Types